• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Fluoxetine and Molnupiravir: A Synergistic Combination for COVID-19 Treatment?氟西汀与莫努匹拉韦：治疗新冠病毒病的协同组合？
Hosp Pharm. 2022 Oct;57(5):603-604. doi: 10.1177/00185787211073465. Epub 2022 Jan 31.
2
Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.奥密克戎（BA.1 和 BA.2）流行期间，临床实践中莫努匹韦和索特罗维单抗在日本 COVID-19 透析患者中的疗效。
Ther Apher Dial. 2023 Dec;27(6):1064-1069. doi: 10.1111/1744-9987.14033. Epub 2023 Jul 3.
3
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro.莫努匹韦与奈玛特韦或GC376联合使用在体外抑制新型冠状病毒复制方面具有协同作用。
Microorganisms. 2022 Jul 21;10(7):1475. doi: 10.3390/microorganisms10071475.
4
Efficacy of molnupiravir and interferon for the treatment of SARS-CoV-2 in golden Syrian hamster.莫努匹韦和干扰素治疗金黄地鼠 SARS-CoV-2 的疗效。
J Med Virol. 2024 Sep;96(9):e29901. doi: 10.1002/jmv.29901.
5
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.莫努匹韦的发现、研发与专利趋势：一种有前景的 COVID-19 口服治疗药物
Molecules. 2021 Sep 24;26(19):5795. doi: 10.3390/molecules26195795.
6
Molnupiravir Revisited-Critical Assessment of Studies in Animal Models of COVID-19.莫努匹韦再探——对 COVID-19 动物模型研究的批判性评估。
Viruses. 2023 Oct 25;15(11):2151. doi: 10.3390/v15112151.
7
Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.奈玛特韦/利托那韦与莫努匹韦在门诊环境下用于 COVID-19 的有效性和不良事件：多中心前瞻性观察研究。
J Korean Med Sci. 2023 Oct 30;38(42):e347. doi: 10.3346/jkms.2023.38.e347.
8
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.莫努匹韦与新冠感染后急性后遗症风险：队列研究。
BMJ. 2023 Apr 25;381:e074572. doi: 10.1136/bmj-2022-074572.
9
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.莫努匹韦治疗免疫功能低下的 COVID-19 患者的疗效、安全性和病毒学结果：来自 3 期随机、安慰剂对照 MOVe-OUT 试验。
Infection. 2023 Oct;51(5):1273-1284. doi: 10.1007/s15010-022-01959-9. Epub 2023 Jan 17.
10
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.Molnupiravir 治疗非住院成人 COVID-19 的 2/3 期试验。
NEJM Evid. 2022 Feb;1(2):EVIDoa2100043. doi: 10.1056/EVIDoa2100043. Epub 2021 Dec 16.

引用本文的文献

1
Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19.选择性5-羟色胺再摄取抑制剂：对抗新冠病毒的新希望。
Front Pharmacol. 2022 Nov 30;13:1036093. doi: 10.3389/fphar.2022.1036093. eCollection 2022.
2
Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19.抗抑郁药的使用及其与新冠病毒住院患者28天死亡率的关联：对FIASMA模型对抗COVID-19的支持
J Clin Med. 2022 Oct 5;11(19):5882. doi: 10.3390/jcm11195882.
3
Potential of as a Capping Agent for Antiviral Nanoparticles against SARS-CoV-2.作为一种用于抗病毒纳米粒子对抗 SARS-CoV-2 的盖帽试剂的潜力。
Biomed Res Int. 2022 Sep 15;2022:5714035. doi: 10.1155/2022/5714035. eCollection 2022.

本文引用的文献

1
Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day.氟西汀的药代动力学和组织分布定量支持在 COVID-19 中以每天至少 20 毫克的剂量发挥治疗作用。
F1000Res. 2021 Jun 16;10:477. doi: 10.12688/f1000research.53275.2. eCollection 2021.
2
Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.COVID-19 患者处方选择性 5-羟色胺再摄取抑制剂抗抑郁药的死亡风险。
JAMA Netw Open. 2021 Nov 1;4(11):e2133090. doi: 10.1001/jamanetworkopen.2021.33090.
3
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.莫努匹拉韦诱导的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）诱变机制。
Nat Struct Mol Biol. 2021 Sep;28(9):740-746. doi: 10.1038/s41594-021-00651-0. Epub 2021 Aug 11.
4
Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis.7 个国家的 COVID-19 患者心理健康障碍与死亡率之间的关联：系统评价和荟萃分析。
JAMA Psychiatry. 2021 Nov 1;78(11):1208-1217. doi: 10.1001/jamapsychiatry.2021.2274.
5
Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?选择性 5-羟色胺再摄取抑制剂的药物再利用：这些药物能帮助对抗 COVID-19 并拯救生命吗？
J Clin Neurosci. 2021 Jun;88:163-172. doi: 10.1016/j.jocn.2021.03.010. Epub 2021 Mar 19.
6
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.瑞德西韦联合氟西汀和伊曲康唑治疗药物协同作用可有效抑制 SARS-CoV-2 体外感染。
Br J Pharmacol. 2021 Jun;178(11):2339-2350. doi: 10.1111/bph.15418. Epub 2021 Apr 6.
7
Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection.氟西汀作为 SARS-CoV-2 感染的抗炎治疗药物。
Biomed Pharmacother. 2021 Jun;138:111437. doi: 10.1016/j.biopha.2021.111437. Epub 2021 Feb 25.
8
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro.氟西汀在体外可抑制新型冠状病毒。
Microorganisms. 2021 Feb 9;9(2):339. doi: 10.3390/microorganisms9020339.
9
The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies.SSRIs 和 SNRIs 在抑郁症治疗中的抗炎作用：对人类和啮齿动物研究的综述。
Inflammopharmacology. 2021 Feb;29(1):75-90. doi: 10.1007/s10787-020-00777-5. Epub 2020 Nov 8.
10
Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.通过临床许可的酸性鞘磷脂酶（FIASMA）功能抑制剂，包括抗抑郁药氟西汀，靶向内溶酶体宿主-SARS-CoV-2 界面。
Emerg Microbes Infect. 2020 Dec;9(1):2245-2255. doi: 10.1080/22221751.2020.1829082.

Fluoxetine and Molnupiravir: A Synergistic Combination for COVID-19 Treatment?

作者信息

Pashaei Yaser

机构信息

Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

出版信息

Hosp Pharm. 2022 Oct;57(5):603-604. doi: 10.1177/00185787211073465. Epub 2022 Jan 31.

DOI:10.1177/00185787211073465
PMID:36081539
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9445536/
Abstract
摘要